Healthcare Stocks Technical Reports -- EnteroMedics, Neovasc, Amedica, and InspireMD

Sep 12, 2016, 07:40 ET from Chelmsford Park SA

NEW YORK, September 12, 2016 /PRNewswire/ --

Today,'s attention is turned to the Medical Appliances and Equipment space which presents some good buying opportunities given the growing demand for Healthcare and the rising number of the aging population. Stocks in focus are: EnteroMedics Inc. (NASDAQ: ETRM), Neovasc Inc. (NASDAQ: NVCN), Amedica Corp. (NASDAQ: AMDA), and InspireMD Inc. (NYSE MKT: NSPR). Download the free research reports on these stocks today:


St. Paul, Minnesota headquartered EnteroMedics Inc.'s stock saw a decline of 10.71%, finishing Friday's trading session at $0.14. A total volume of 7.07 million shares was traded, which are above their three months average volume of 4.22 million shares. The Company's shares are trading below their 50-day moving average by 37.60%. Additionally, shares of EnteroMedics, which focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders, have a Relative Strength Index (RSI) of 26.08.

On September 07th, 2016, EnteroMedics announced the appointment of Scott Youngstrom as Chief Financial Officer and Chief Compliance Officer, effective October 3rd, 2016. Scott will succeed Greg Lea, EnteroMedics' current Chief Financial Officer and Chief Compliance Officer, who will be retiring from the Company effective October 3, 2016. Mr. Youngstrom brings to EnteroMedics over 25 years of strategic financial and operational experience in a variety of medical device companies, most recently having served as Chief Financial Officer and Vice President, Finance at Galil Medical, a leading developer of cryotherapy technology. Prior to Galil Medical, from 2009 to 2014, Mr. Youngstrom served as Vice President, Chief Operating Officer, and Chief Financial Officer at DGIMED Ortho, Inc., a developer of orthopedic medical devices. See our free and comprehensive research report on ETRM at:


Shares in Richmond, Canada headquartered Neovasc Inc. ended the session at $0.58, which was a drop of 3.13%. The stock recorded a trading volume of 447,589 shares. The Company's shares have gained 43.05% in the previous three months and are trading 2.31% above their 50-day moving average. Moreover, shares of Neovasc, which develops, manufactures, and markets cardiovascular products worldwide, have an RSI of 48.77.

On August 9th, 2016 Neovasc reported that revenues for the three months ended June 30th, 2016, were $1.71 million compared to revenues of $2.97 million for the same period in 2015, representing a decrease of 42%. The operating losses and comprehensive losses for the three months ended June 30th, 2016 were $83.69 million and $83.06 million, respectively, or $1.25 basic and diluted loss per share, as compared with losses of $6.75 million and $5.30 million, or $0.10 basic and diluted loss per share for the same period in 2015. The primary increase in the operating loss was attributed to a $70 million contingent liability related to the jury award against the Company in its litigation with CardiAQ. NVCN free research report PDF is just a click away at:


On Friday, shares in Salt Lake City, Utah headquartered Amedica Corp. recorded a trading volume of 879,407 shares. The stock rose 1.22%, closing the day at $0.91. The Company's shares have gained 18.16% in the last one month. The stock is trading 3.93% above its 50-day moving average. Additionally, shares of Amedica, which develops, manufactures, and sells a range of medical devices based on its silicon nitride ceramic technology platform in the US, Europe, and South America, have an RSI of 51.58.

On August 24th, 2016, Amedica announced that the U.S. FDA's clearance of expanded Valeo® II Lateral Lumbar sizes. The additional sizes of the Valeo II LL interbody fusion device will be commercially available August 29th, 2016 The Valeo II LL interbody fusion device is made entirely of Amedica's proprietary medical grade silicon nitride ceramic -- an ideal material for fusion, due to its inherent osteoconductivity, anti-infective properties, bone-like imaging (artifact-free & radiotranslucent), and exceptional strength. The system includes second generation instrumentation to improve patient safety and surgeon ease of use. Sign up for your complimentary report on AMDA at:


At the close, shares in Boston, Massachusetts headquartered InspireMD Inc. recorded a trading volume of 357,726 shares. The stock ended the session at $0.13, up 0.47%. The Company's shares are trading below their 50-day moving average by 28.72%. Furthermore, shares of InspireMD, which focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex coronary and vascular diseases, have an RSI of 34.55.

On September 07th, 2016, InspireMD announced the appointment of Thomas Kester to the Company's Board of Directors and Chairman of the Company's Audit Committee. Mr. Kester's experience includes 28 years at KPMG LLP, including 18 years as an audit partner. Register for free on and download the latest research report on NSPR at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA